Deep learning and virtual drug screening.

Area of Science:

• Drug discovery and medicinal chemistry
• Computational chemistry
• Bioinformatics

Background:

• Current drug development is hindered by high costs and slow timelines.
• Technological advancements in drug discovery necessitate more efficient methods.
• Machine learning (ML) offers a promising approach to accelerate the identification of drug leads.

Purpose of the Study:

• To explain the integration of virtual screening (VS) and ML in drug discovery.
• To discuss the application of artificial neural networks (ANNs) for VS.
• To highlight advancements in ANNs that enhance their utility in predicting drug-target interactions.

Main Methods:

• Integration of virtual screening (VS) and machine learning (ML) principles.
• Application of artificial neural networks (ANNs) as a classification tool for VS.
• Utilizing techniques like dropout, multitask learning, and convolution to improve ANN performance.

Main Results:

• ANNs demonstrate significant utility in both structure-based and ligand-based VS.
• Advanced ANN techniques enhance the accuracy and chemical interpretability of VS.
• ML-driven VS shows potential for more efficient and accurate generation of drug leads.

Conclusions:

• Machine learning, particularly ANNs, is revolutionizing drug discovery by improving the efficiency and accuracy of virtual screening.
• Advanced ANN methodologies enable deeper chemical insights into drug-target binding activities.
• The integration of ML and VS is crucial for overcoming the limitations of traditional drug development pipelines.